Vanda Pharmaceuticals reported $-10.28M in EBIT for its fiscal quarter ending in December of 2024.





Ebit Change Date
Acadia Pharmaceuticals USD -4.62M 22.01M Mar/2026
Agios Pharmaceuticals USD -110.02M 11.55M Mar/2026
Akebia Therapeutics USD -5.45M 9.4M Dec/2025
Alnylam Pharmaceuticals USD 137.59M 108.19M Mar/2026
Anika Therapeutics USD 646K 3.88M Dec/2025
Arrowhead Research USD -141.26M 182.07M Mar/2026
AstraZeneca USD 7.11B 4.14B Mar/2026
Bristol-Myers Squibb USD 3.56B 90M Mar/2026
Eli Lilly USD 9.78B 792M Mar/2026
Enanta Pharmaceuticals USD -23.54M 6.31M Dec/2024
Esperion Therapeutics USD 85.23M 95.19M Dec/2025
Halozyme Therapeutics USD -61.77M 26.64M Mar/2026
Heron Therapeutics USD 38K 3.83M Dec/2025
Insmed USD -200.28M 49.43M Mar/2026
J&J USD 6.62B 1.51B Mar/2026
Lexicon Pharmaceuticals USD -14.78M 2.59M Dec/2025
Ligand Pharmaceuticals USD 60.33M 1.76M Mar/2026
Merck USD -1.88B 8.12B Mar/2026
Minerva Neurosciences USD -4.37M 1.71M Sep/2024
Moderna USD -1.39B 531M Mar/2026
Novartis USD 4.06B 413M Dec/2025
Pfizer USD 4.99B 340M Mar/2026
PTC Therapeutics USD 45.89M 127.51M Mar/2026
Puma Biotechnology USD -2.2M 11.41M Jun/2024
Sanofi EUR 1.94B 239M Mar/2026
Takeda JPY -13.62B 271.11B Mar/2026
Teva Pharmaceutical Industries USD 758M 181M Mar/2026
Ultragenyx Pharmaceutical USD -216M 102M Mar/2026
Vanda Pharmaceuticals USD -10.28M 721K Dec/2024
Veracyte USD 19.08M 5.55M Mar/2026